CMBA
LCTX icon

C.M. Bidwell & Associates’s Lineage Cell Therapeutics LCTX Stock Holding History

C.M. Bidwell & Associates’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-9,310
Closed -$22K – 427
2018
Q1 		$22K Hold
9,310
– – 0.02% 284
2017
Q4 		$18K Buy
+9,310
New +$20.3K 0.02% 289

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
IA
IndexIQ Advisors New York $2.82B AUM 12.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

C.M. Bidwell & Associates's LCTX Position: Q2 2018 in Review

C.M. Bidwell & Associates sold out of Lineage Cell Therapeutics (LCTX) in Q2 2018, closing a stake of 9,310 shares — an estimated $22K sold.

C.M. Bidwell & Associates first reported a position in LCTX in Q4 2017 and held it in 2 quarters. The position peaked at $22K in Q1 2018. 107 funds tracked by Wall St. Rank hold LCTX as of Q2 2018.

  • C.M. Bidwell & Associates reported no remaining Lineage Cell Therapeutics position as of Q2 2018 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 9,310 Lineage Cell Therapeutics shares in Q2 2018, an estimated $22K.
  • C.M. Bidwell & Associates first reported a position in Lineage Cell Therapeutics in Q4 2017 and held it in 2 quarters.
  • C.M. Bidwell & Associates's Lineage Cell Therapeutics position peaked at $22K in Q1 2018.
  • 107 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2018.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2018, filed 13 Aug 2018.